STOCK TITAN

Travere Therapeutics (TVTX) Financials

TVTX NASDAQ
Trailing 12 months to September 30, 2026
Revenue $651.0M +49.4% YoY
Net Income -$121.5M n/m YoY
EPS (Diluted) -$1.29 n/m YoY
Operating Cash Flow $176.6M n/m YoY
Market Cap $4.9B as of Nov 13, 2026
Price / Sales 7.5x on $651.0M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 215x on $22.6M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TVTX SEC filings page.

Travere Therapeutics, Inc. (TVTX) reported $651.0M in revenue over the twelve months to Sep 30, 2026, up 49.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TVTX FY2025

FY2025 revenue expansion brought operating losses close to break-even, but working capital became more dependent on collecting receivables.

Revenue more than doubled to $491M while operating cash flow shifted from -$237M in FY2024 to positive $38M in FY2025, marking a cash-conversion turn rather than growth funded solely by external capital. Yet receivables rose 195.5% to $80M as current liabilities fell 20.3%, so the cash improvement coexists with more reported sales tied up in customer balances.

The profit improvement came largely below gross profit: R&D spending fell to $206M, while operating margin improved to -12.8%, indicating the turnaround reflects both scale and reduced development intensity. Gross margin reached 97.9%, only 1.2 percentage points above FY2024, so product-level economics changed less than operating costs did.

Short-term coverage was represented by a 2.7x current ratio, indicating current assets exceeded current obligations. However, liabilities represented 81.0% of assets and debt-to-equity was 2.7x, leaving the balance sheet reliant on substantial creditor financing.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 73 / 100
Financial Health Score 73/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Travere Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
87

Travere Therapeutics, Inc. held $322.8M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $37.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Travere Therapeutics, Inc. scores 87/100 among other emerging companies.

Dilution
57

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Travere Therapeutics, Inc. scores 57/100 on it among other emerging companies.

R&D Intensity
67

Travere Therapeutics, Inc. spent $206.0M on research and development in fiscal year 2025, which was 37.2% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Travere Therapeutics, Inc. scores 67/100 among other emerging companies.

Revenue Progress
84

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Travere Therapeutics, Inc. scores 84/100 on it among other emerging companies.

Burn Trend
92

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Travere Therapeutics, Inc. scores 92/100 on it among other emerging companies.

Balance Sheet
50

Travere Therapeutics, Inc.'s cash, cash equivalents and investments came to $322.8M at the end of fiscal year 2025, against $490.4M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Travere Therapeutics, Inc. scores 50/100 among other emerging companies.

Altman Z-Score Safe
3.56

Travere Therapeutics, Inc. scores 3.56, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $4.9B against total liabilities of $490.4M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong
7/9

Travere Therapeutics, Inc. passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed
N/A

Travere Therapeutics, Inc. reported a net loss of $25.5M while generating $37.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Travere Therapeutics, Inc. reported an operating loss of $62.8M against $10.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$224.6M
YoY+36.2%
QoQ+32.4%
5Y CAGR+26.9%
10Y CAGR+20.8%

Travere Therapeutics, Inc. generated $224.6M in revenue in Q3 2026. This represents an increase of 36.2% from the same quarter a year earlier. Against the prior quarter it is up 32.4%.

EBITDA
-$62.9M
YoY-254.5%
QoQ-868.3%

Travere Therapeutics, Inc.'s EBITDA was -$62.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 254.5% from the same quarter a year earlier. Against the prior quarter it is down 868.3%.

Net Income
-$52.3M
YoY-303.6%
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Travere Therapeutics, Inc. reported a net loss of $52.3M in Q3 2026. This represents a decrease of 303.6% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.55
YoY-296.4%
QoQn/m
5Y CAGRn/m

Travere Therapeutics, Inc. earned -$0.55 per diluted share (EPS) in Q3 2026. This represents a decrease of 296.4% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Cash & Debt
$123.5M
YoY+11.4%
QoQ+4.9%
5Y CAGR-3.8%
10Y CAGR+17.9%

Travere Therapeutics, Inc. held $123.5M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
96M
YoY+7.3%
QoQ+1.8%
5Y CAGR+9.4%

Travere Therapeutics, Inc. had 96M shares outstanding in Q3 2026. This represents an increase of 7.3% from the same quarter a year earlier. Against the prior quarter it is up 1.8%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
98.7%
YoY-0.3pp
QoQ0.0pp

Travere Therapeutics, Inc.'s gross margin was 98.7% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 0.3 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.

Operating Margin
-30.3%
YoY-45.5pp
QoQ-32.7pp
5Y change+16.2pp
10Y change+29.7pp

Travere Therapeutics, Inc.'s operating margin was -30.3% in Q3 2026, reflecting core business profitability. This is down 45.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 32.7 percentage points.

Net Margin
-23.3%
YoY-38.9pp
QoQ-2.8pp
5Y change+28.9pp

Travere Therapeutics, Inc.'s net profit margin was -23.3% in Q3 2026, showing the share of revenue converted to profit. This is down 38.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.8 percentage points.

Return on Equity
-231.7%
YoY-266.7pp
QoQ-89.8pp

Travere Therapeutics, Inc.'s quarterly ROE was -231.7% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 266.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 89.8 percentage points.

Capital Allocation

R&D Spending
$70.3M
YoY+35.5%
QoQ+16.6%

Travere Therapeutics, Inc. invested $70.3M in research and development in Q3 2026. This represents an increase of 35.5% from the same quarter a year earlier. Against the prior quarter it is up 16.6%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

TVTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TVTX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$224.6M+36.2%$169.6M+48.2%$127.2M+55.6%$129.7M+73.4%$164.9M+162.1%$114.4M+111.5%$81.7M+97.5%$74.8M+66.0%
Cost of Revenue$2.9M+80.9%$2.2M+42.9%$1.9M-58.3%$2.6M0.0%$1.6M-2.5%$1.5M-26.2%$4.7M+211.1%$2.6M
Gross Profit$221.7M+35.8%$167.4M+48.2%$125.2M+62.5%$127.1M+76.0%$163.3M+166.5%$112.9M+116.9%$77.1M+93.3%$72.2M
R&D Expenses$70.3M+35.5%$60.3M+22.1%$57.1M+21.8%$57.9M-6.8%$51.9M+0.4%$49.4M-9.1%$46.9M-5.1%$62.1M
SG&A Expenses$98.4M+38.5%$96.1M+53.6%$80.3M+32.8%$127.8M+83.8%$71.0M+8.3%$62.6M-3.4%$60.4M-5.9%$69.5M
Operating Income-$68.1M-373.2%$4.0Mn/m-$36.9Mn/m-$32.4Mn/m$24.9Mn/m-$12.7Mn/m-$42.7Mn/m-$60.7Mn/m
EBITDA-$62.9M-254.5%$8.2M+499.4%-$11.7Mn/m-$14.3Mn/m$40.7Mn/m$1.4Mn/m-$29.9Mn/m-$48.6Mn/m
Interest Expense$2.1M-22.2%$2.1M-25.0%$2.3M-19.5%$2.3M-18.6%$2.8M-0.9%$2.8M+2.1%$2.9M+2.0%$2.8M
Income Tax-$5.9M-73787.5%-$204K-1120.0%-$120K-407.7%$921Kn/m$8Kn/m$20K-76.5%$39K-79.6%-$72K
Net Income-$52.3M-303.6%-$34.8Mn/m-$37.1Mn/m$2.7Mn/m$25.7Mn/m-$12.8Mn/m-$41.2Mn/m-$60.3Mn/m
EPS (Basic)-$0.55-289.7%-$0.37n/m-$0.40n/m$0.03n/m$0.29n/m-$0.14n/m-$0.47n/m-$0.71n/m
EPS (Diluted)-$0.55-296.4%-$0.37n/m-$0.40n/m$0.03n/m$0.28n/m-$0.14n/m-$0.47n/m-$0.71n/m
Diluted Shares (Avg)95M-7.8%93M+5.1%92M+4.0%N/A103M+31.9%89M+14.8%88M+14.5%N/A

TVTX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TVTX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-Q
Total Assets$848.2M+57.5%$799.4M+43.9%$555.2M+1.2%$605.2M+1.9%$538.6M+6.8%$555.3M+0.8%$548.8M-17.3%$594.1M-24.7%
Current Assets$633.4M+70.7%$615.1M+62.1%$392.7M+4.9%$437.6M+5.0%$371.1M+14.3%$379.6M+2.9%$374.2M-22.2%$416.7M-32.4%
Cash & Equivalents$123.5M+11.4%$117.7M+56.7%$78.4M+26.6%$93.0M+58.9%$110.9M+204.7%$75.2M+132.7%$61.9M+43.1%$58.5M+0.6%
Short-Term Investments$179.8M+29.7%$175.9Mn/m$130.6Mn/m$145.4Mn/m$138.7M-36.7%$0-100.0%$0-100.0%$0-100.0%
Inventory$43.8M+16.7%$40.0M+6.3%$37.1M-2.5%$36.2M-13.6%$37.5M-12.4%$37.7M-12.3%$38.0M-10.2%$41.9M+344.8%
Accounts Receivable$107.5M+29.6%$80.6M+108.3%$87.3M+153.9%$80.1M+195.5%$83.0M+229.7%$38.7M+58.3%$34.4M+51.3%$27.1M+28.0%
Long-Term Investments$168.4M+3306.3%$195.5Mn/m$55.7Mn/m$84.4Mn/m$4.9M-77.6%$0-100.0%$0-100.0%$0-100.0%
GoodwillN/AN/AN/AN/A$800K0.0%$800K0.0%$800K0.0%$800K0.0%
Total Liabilities$825.6M+77.6%$774.8M+48.3%$456.5M-11.5%$490.4M-8.4%$465.0M-13.1%$522.6M-2.5%$516.0M-12.5%$535.0M-9.0%
Current Liabilities$210.9M+56.1%$152.0M-19.8%$125.4M-31.3%$159.9M-20.3%$135.1M-28.9%$189.5M+56.3%$182.5M+5.3%$200.8M+12.8%
Non-Current Liabilities$614.7M+86.3%$622.8M+87.0%$331.0M-0.7%$330.5M-1.1%$329.9M-4.3%$333.0M-19.7%$333.5M-19.9%$334.3M-18.5%
Long-Term DebtN/AN/AN/A$311.7M+0.5%$311.4M+0.5%$311.0M-17.7%$310.7M-17.7%$310.3M-17.7%
Total Equity$22.6M-69.3%$24.5M-25.1%$98.7M+200.8%$114.8M+94.4%$73.6Mn/m$32.7M+116.2%$32.8M-55.7%$59.1M-70.6%
Retained Earnings-$1.6Bn/m-$1.5Bn/m-$1.5Bn/m-$1.5Bn/m-$1.5Bn/m-$1.5Bn/m-$1.5Bn/m-$1.4Bn/m

TVTX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TVTX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$109.1M+662.1%$47.2M+846.5%-$40.4Mn/m$60.7Mn/m$14.3Mn/m$5.0Mn/m-$42.2Mn/m-$35.7Mn/m
Depreciation & Amortization$5.2M-67.1%$4.2M-69.8%$25.2M+96.9%$18.1M+50.0%$15.8M+40.5%$14.0M+35.5%$12.8M+29.6%$12.1M+27.4%
Stock-Based Compensation$23.4M+108.1%$21.8M+104.6%$16.1M+40.5%N/A$11.3M+40.4%$10.6M+7.3%$11.5M+17.8%N/A
Capital ExpendituresN/AN/AN/AN/A$140Kn/mN/AN/AN/A
Free Cash FlowN/AN/AN/AN/A$14.2Mn/mN/AN/AN/A
Investing Cash Flow-$119.6M-238.2%-$206.3M-4353.3%$21.5M-47.8%-$104.8Mn/m$86.6M+87.7%$4.8M-83.0%$41.3M-60.6%-$80.3Mn/m
Financing Cash Flow$27.3Mn/m$187.5M+12613.0%$4.2M+13.1%$26.7M-80.8%-$65.3M-142141.3%$1.5M+88.6%$3.7Mn/m$139.1M+112092.7%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

TVTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TVTX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin98.7%-0.3pp98.7%0.0pp98.5%+4.2pp98.0%+1.4pp99.0%+1.6pp98.7%+2.5pp94.3%-2.1pp96.6%
Operating Margin-30.3%-45.5pp2.3%+13.4pp-29.0%+23.2pp-25.0%+56.2pp15.1%+104.4pp-11.1%-52.2%-81.2%
Net Margin-23.3%-38.9pp-20.5%-9.4pp-29.2%+21.3pp2.1%+82.7pp15.6%+102.7pp-11.1%-50.4%-80.6%
Return on Equity-231.7%-266.7pp-141.9%-103.0pp-37.6%+88.0pp2.4%+104.4pp34.9%-39.0%+425.9pp-125.6%+58.1pp-102.0%-57.1pp
Return on Assets-6.2%-10.9pp-4.3%-2.0pp-6.7%+0.8pp0.4%+10.6pp4.8%+15.6pp-2.3%+10.5pp-7.5%+13.0pp-10.1%+1.3pp
Current Ratio3.00+0.3x4.05+2.0x3.13+1.1x2.74+0.7x2.75+1.0x2.00-1.0x2.05-0.7x2.08-1.4x
Debt-to-EquityN/AN/AN/A2.71-2.5x4.239.50-15.5x9.46+4.4x5.25+3.4x
Liabilities-to-Equity36.56+30.2x31.60+15.6x4.62-11.1x4.27-4.8x6.3215.96-19.4x15.72+7.8x9.06+6.1x
Asset Turnover0.260.0x0.210.0x0.23+0.1x0.21+0.1x0.31+0.2x0.21+0.1x0.15+0.1x0.13+0.1x
FCF MarginN/AN/AN/AN/A8.6%+76.2ppN/AN/AN/A

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Travere Therapeutics, Inc. TVTX FY2025 $490.7M -$25.5M -5.2% $4.9B 73/100
Edgewise Therapeutics, Inc. EWTX FY2025 N/A -$167.8M N/A $5.0B —
Ionis Pharmaceuticals, Inc. IONS FY2025 $943.7M -$381.4M -40.4% $4.8B 70/100
PTC Therapeutics, Inc. PTCT FY2025 $1.7B $682.6M 39.4% $5.3B 63/100
Cogent Biosciences, Inc. COGT FY2025 N/A -$328.9M N/A $5.0B —
Scholar Rock Holding Corporation SRRK FY2025 $0 -$377.9M N/A $5.3B —

Frequently Asked Questions

Travere Therapeutics, Inc. (TVTX) reported $490.7M in total revenue for fiscal year 2025. This represents a 110.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Travere Therapeutics, Inc. (TVTX) revenue grew by 110.5% year-over-year, from $233.2M to $490.7M in fiscal year 2025.

No, Travere Therapeutics, Inc. (TVTX) reported a net loss of $121.5M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $25.5M, with a net profit margin of -5.2%.

Travere Therapeutics, Inc. (TVTX) reported diluted earnings per share of -$0.29 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Travere Therapeutics, Inc. (TVTX) had EBITDA of -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Travere Therapeutics, Inc. (TVTX) had $93.0M in cash and equivalents against $311.7M in long-term debt.

Travere Therapeutics, Inc. (TVTX) had a gross margin of 97.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Travere Therapeutics, Inc. (TVTX) had an operating margin of -12.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Travere Therapeutics, Inc. (TVTX) had a net profit margin of -5.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Travere Therapeutics, Inc. (TVTX) has a return on equity of -22.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Travere Therapeutics, Inc. (TVTX) generated $37.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Travere Therapeutics, Inc. (TVTX) had $605.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Travere Therapeutics, Inc. (TVTX) invested $206.0M in research and development during fiscal year 2025.

Travere Therapeutics, Inc. (TVTX) had 92M shares outstanding as of fiscal year 2025.

Travere Therapeutics, Inc. (TVTX) had a current ratio of 2.74 as of fiscal year 2025, which is generally considered healthy.

Travere Therapeutics, Inc. (TVTX) had a debt-to-equity ratio of 2.71 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Travere Therapeutics, Inc. (TVTX) had a liabilities-to-equity ratio of 4.27 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Travere Therapeutics, Inc. (TVTX) had a return on assets of -4.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Travere Therapeutics, Inc. (TVTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $4.9B as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Travere Therapeutics, Inc. (TVTX) trades at 7.5x sales, its market capitalization divided by $651.0M revenue, trailing 12 months to September 30, 2026. The market capitalization is $4.9B as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Travere Therapeutics, Inc. (TVTX) has an Altman Z-Score of 3.56, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Travere Therapeutics, Inc. (TVTX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Travere Therapeutics, Inc. (TVTX) reported a net loss of $25.5M while generating $37.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Travere Therapeutics, Inc. (TVTX) reported an operating loss of $62.8M against $10.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Travere Therapeutics, Inc. (TVTX) scores 73 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top